Boston Trust Walden Corp Sells 2,085 Shares of InMode Ltd. (NASDAQ:INMD)

Boston Trust Walden Corp decreased its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 0.2% in the first quarter, HoldingsChannel reports. The fund owned 1,365,291 shares of the healthcare company’s stock after selling 2,085 shares during the quarter. Boston Trust Walden Corp’s holdings in InMode were worth $24,220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of INMD. Orion Capital Management LLC bought a new stake in shares of InMode during the 4th quarter valued at $65,000. SBI Securities Co. Ltd. bought a new stake in shares of InMode during the 4th quarter valued at $87,000. Farther Finance Advisors LLC grew its position in shares of InMode by 26.2% during the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company’s stock valued at $93,000 after acquiring an additional 1,154 shares during the period. Covestor Ltd grew its position in shares of InMode by 13.9% during the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company’s stock valued at $99,000 after acquiring an additional 723 shares during the period. Finally, Lazard Asset Management LLC grew its position in shares of InMode by 6,128.7% during the 4th quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company’s stock valued at $105,000 after acquiring an additional 6,190 shares during the period. Institutional investors own 68.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. UBS Group dropped their target price on shares of InMode from $19.00 to $16.25 and set a “neutral” rating for the company in a report on Tuesday, April 29th. Baird R W downgraded shares of InMode from a “strong-buy” rating to a “hold” rating in a report on Monday, April 28th. BTIG Research downgraded shares of InMode from a “buy” rating to a “neutral” rating in a report on Tuesday, April 29th. Canaccord Genuity Group dropped their target price on shares of InMode from $17.00 to $15.00 and set a “hold” rating for the company in a report on Tuesday, April 29th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a report on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $18.54.

InMode Stock Down 0.2%

INMD opened at $13.34 on Friday. The firm has a 50-day simple moving average of $14.54 and a two-hundred day simple moving average of $16.60. InMode Ltd. has a 52 week low of $13.16 and a 52 week high of $19.85. The company has a market capitalization of $843.22 million, a PE ratio of 5.73 and a beta of 1.98.

InMode (NASDAQ:INMD) last released its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.14). InMode had a net margin of 44.79% and a return on equity of 17.17%. The company had revenue of $77.87 million for the quarter, compared to the consensus estimate of $82.21 million. During the same period last year, the company earned $0.32 EPS. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. As a group, sell-side analysts expect that InMode Ltd. will post 1.75 earnings per share for the current year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.